ClinicaliQ Trial Snapshot
- Benefits of Retained Insulin for Good Health — Recruiting • Diabetes / Metabolic • NCT07828626.
- What is being tested: The clinical impact of retained endogenous insulin production (measured by C-peptide levels) on quality of life and health outcomes in patients requiring insulin therapy, with specific focus on type 1 diabetes populations.
- Patient eligibility overview: The trial includes adults living with insulin-treated diabetes, with particular emphasis on individuals with type 1 diabetes who have varying degrees of residual beta cell function.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this research is to understand the impact of retained endogenous insulin (as measured by C-peptide) on quality of life and related outcomes in people living with insulin treated diabetes, and, in those living with type 1 diabetes, to determine the pragmatic and non-pragmatic C-peptide measures which have the strongest association with clinical benefit (including repeated home samples and derived measures of beta cell function). The investigators will do this in two ways: Firstly, the investigators will extend a large existing prospective study of new adult onset diabetes…
Eligibility Snapshot
- ARM 1 Inclusion Criteria: * Previously recruited to the StartRight study (NCT03737799) with consent to be contacted for further research * Clinical diagnosis of diabetes & Insulin treated * Able and willing to provide informed consent/assent. * Aged 18 years or older. ARM 2 Inclusion Criteria: * Clinical diagnosis of Type 1 diabetes * Known C-peptide, measured as part of previous research or as part of diabetes clinical care OR Where C-peptide is not measured, participant must be within 7 years of diagnosis and have at least 1 positive islet antibody, measured at any time since diabetes diagnosis. * Where measured C-peptide is >600pmol/L, previous positive islet autoantibodies. * Able and willing to provide informed consent * Aged 18 years or older
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.